Manufacturing Capacity Expansion
We are delighted to announce the addition of a sixth global site that will augment cGMP manufacturing capacity for mammalian biologics, driven by increased customer demand for 2000L bioreactors. Read more from our MD Jonathan Goldman and President Kimball Hall.Read More
Information on Abzena’s Response to COVID-19
The COVID-19 pandemic is a global public health issue of concern to all. Read more to find the latest on our detailed efforts to ensure the health and well-being of our employees, as well as our business continuity plan for our partner clients at our three sites in the US and UK.Read More
Sonnet BioTherapeutics selects Abzena as clinical stage manufacturing partner
The clinical stage biopharmaceutical company developing innovative targeted biologic drugs, announced it has selected Abzena as its manufacturing partner for SON-1010, an IL-12-FHAB cytokineRead More
Technologies and Solutions
Abzena provides proprietary technologies and complementary solutions to organisations involved in the development of biopharmaceutical products.
Latest News and Events
Abzena presents its latest research and exhibits at events all over the world.
Find out where we are next and our latest news below.
Abzena selected by Immunome to develop and manufacture antibody cocktail for Immunome’s COVID-19 Antibody Based Treatment
World ADC Europe 2021
9 March 2021
Abzena announces opening of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors
Resources and Downloads
Find our latest videos, brochures and fact sheets in our resources section.
Download our Brochure
Technology & Solutions BrochureDownload File
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs)…Read More
Cell Line Development Lab Tour
Abzena has over 10 years experience in Cell Line Development for customers and has completed…